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Comparison of Inappropriate Shocks and Other Health Outcomes
Between Single- and Dual-Chamber Implantable CardioverterDeﬁbrillators for Primary Prevention of Sudden Cardiac Death:
Results From the Cardiovascular Research Network Longitudinal
Study of Implantable Cardioverter-Deﬁbrillators
Pamela N. Peterson, MD, MSPH; Robert T. Greenlee, PhD, MPH; Alan S. Go, MD; David J. Magid, MD, MPH; Andrea Cassidy-Bushrow, PhD;

Romel Garcia-Montilla, MD; Karen A. Glenn, BS; Jerry H. Gurwitz, MD; Stephen C. Hammill, MD; John Hayes, MD; Alan Kadish, MD;
Kristi Reynolds, PhD, MPH; Param Sharma, MD; David H. Smith, PhD; Paul D. Varosy, MD; Humberto Vidaillet, MD; Chan X. Zeng,
PhD; Sharon-Lise T. Normand, PhD; Frederick A. Masoudi, MD, MSPH
Background-—In US clinical practice, many patients who undergo placement of an implantable cardioverter-deﬁbrillator (ICD) for
primary prevention of sudden cardiac death receive dual-chamber devices. The superiority of dual-chamber over single-chamber
devices in reducing the risk of inappropriate ICD shocks in clinical practice has not been established. The objective of this study
was to compare risk of adverse outcomes, including inappropriate shocks, between single- and dual-chamber ICDs for primary
prevention.
Methods and Results-—We identiﬁed patients receiving a single- or dual-chamber ICD for primary prevention who did not have an
indication for pacing from 15 hospitals within 7 integrated health delivery systems in the Longitudinal Study of Implantable
Cardioverter-Deﬁbrillators from 2006 to 2009. The primary outcome was time to ﬁrst inappropriate shock. ICD shocks were
adjudicated for appropriateness. Other outcomes included all-cause hospitalization, heart failure hospitalization, and death.
Patient, clinician, and hospital-level factors were accounted for using propensity score weighting methods. Among 1042 patients
without pacing indications, 54.0% (n=563) received a single-chamber device and 46.0% (n=479) received a dual-chamber device. In
a propensity-weighted analysis, device type was not signiﬁcantly associated with inappropriate shock (hazard ratio, 0.91; 95%
conﬁdence interval, 0.59–1.38 [P=0.65]), all-cause hospitalization (hazard ratio, 1.03; 95% conﬁdence interval, 0.87–1.21
[P=0.76]), heart failure hospitalization (hazard ratio, 0.93; 95% conﬁdence interval, 0.72–1.21 [P=0.59]), or death (hazard ratio,
1.19; 95% conﬁdence interval, 0.93–1.53 [P=0.17]).
Conclusions-—Among patients who received an ICD for primary prevention without indications for pacing, dual-chamber devices
were not associated with lower risk of inappropriate shock or differences in hospitalization or death compared with single-chamber
devices. This study does not justify the use of dual-chamber devices to minimize inappropriate shocks. ( J Am Heart Assoc.
2017;6:e006937. DOI: 10.1161/JAHA.117.006937.)
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patients receiving primary prevention ICDs. We further
evaluated outcomes of hospitalization and death.

What Is New?
• In this large observational study of a contemporary population of patients receiving an implantable cardioverterdeﬁbrillator for primary prevention who did not have an
indication for pacing, there was no association between the
use of a dual-chamber deﬁbrillator compared with a singlechamber device with respect to the risk of inappropriate
shocks, hospitalization, or death.

What Are the Clinical Implications?
• Given the higher costs and known higher risks of
complications associated with dual-chamber devices, this
study does not support their use in patients receiving a
primary prevention ICD when there is no indication for
pacing.

A

mong patients receiving an implantable cardioverterdeﬁbrillator (ICD) for primary prevention of sudden
cardiac death, a central decision is whether to implant a
single- or dual-chamber device. Dual-chamber devices are
appropriate in patients who require pacing. However, they
are used in more than half of patients without a pacing
indication, a practice that varies widely by institution and is
largely unrelated to patient characteristics.1,2 Compared with
single-chamber devices, dual-chamber devices are more
complex and costly and are associated with more complications and no difference in hospitalizations or mortality.3
Yet, dual-chamber devices may theoretically offer improved
arrhythmia discrimination and reduction in inappropriate
therapies.
Dual-chamber ICDs might be used in patients without an
indication for pacing in the hopes of reducing the risks of
inappropriate shocks, an important complication that can
cause pain, anxiety, depression, and impaired quality of life.4,5
Further, inappropriate shocks may be proarrhythmic and are
associated with higher mortality.6–8 The most common cause
for inappropriate shocks is supraventricular tachycardia
incorrectly identiﬁed by the device as a lethal ventricular
tachyarrhythmia.9 Dual-chamber ICDs may have enhanced
arrhythmia discrimination, which, in theory, might reduce
inappropriate shocks caused by supraventricular tachycardia.
However, existing data regarding the beneﬁts of dual-chamber
devices with respect to inappropriate therapies are inconclusive.10–17
Accordingly, the primary aim of this study was to compare
the risks of inappropriate ICD shocks between single- and
dual-chamber devices among patients without an indication
for pacing in the LS-ICD (Longitudinal Study of Implantable
Cardioverter-Deﬁbrillators),18 in a community-based cohort of
DOI: 10.1161/JAHA.117.006937

Methods
Data Sources
The Cardiovascular Research Network (CVRN) LS-ICD has
been previously described in detail.18 The data for this
study were derived from: (1) the National Cardiovascular
Data Registry (NCDR) ICD Registry; (2) the CVRN virtual
data warehouse, which includes information from each
health plan’s electronic medical record and administrative
databases; and (3) a database of ICD-delivered therapies.
Pacing indications, device type, clinical characteristics, and
provider characteristics were collected from the NCDR ICD
Registry.19 The NCDR implements a data quality program
that includes data and range checks, outlier analysis, and
random audits.20 All hospitals participating in this study
report data to the NCDR on all ICD implants regardless of
payer or indication. Data on outcomes of hospitalization
and death were obtained from the CVRN virtual data
warehouse.
Data on inappropriate shocks were obtained from the
ICD therapy database.18 In brief, data on arrhythmia
episodes resulting in device therapies were collected from
device interrogation reports and medical records at the
study sites. Board-certiﬁed electrophysiologists reviewed
intracardiac electrograms and relevant clinical notes to
adjudicate each therapy as appropriate, inappropriate, or
uncertain. Two adjudicators reviewed each therapy independently. Discrepancies in appropriateness determinations
were resolved by conference of reviewer pairs or review by
an additional adjudicator. Institutional review boards at
participating sites approved the study and a waiver of
informed consent was obtained because of the study
design.

Study Population
Consecutive adult patients (aged >18 years) undergoing ﬁrsttime ICD implantation for the primary prevention of sudden
cardiac death in 15 hospitals within 7 integrated healthcare
delivery systems in the CVRN between January 1, 2006, and
December 31, 2009 (n=2787) were identiﬁed. We excluded
patients not enrolled in one of the 7 CVRN health plans at the
time of implantation (n=431), those with a left ventricular
ejection fraction >0.35 (n=57), those with a prior tachycardic
arrest (n=34), and those who received a biventricular device
(n=722). We further excluded those with a documented
indication for pacing (n=501). Pacing indications were ascertained from NCDR data and included: second- or third-degree
Journal of the American Heart Association
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site. Follow-up time for death and hospitalization was up to
6 years.

Patient Characteristics
Outcomes
The primary outcome was time to ﬁrst inappropriate shock.
Therapies were deemed appropriate, inappropriate or uncertain using standardized deﬁnitions developed by the expert
panel based on literature. Follow-up time for device therapy
was as long as 3 years.
Secondary end points included time to all-cause hospitalization, heart failure hospitalization, and all-cause death.
Hospitalizations were ascertained from the virtual data
warehouse, which includes diagnoses for all hospitalizations,
including those outside of health plan facilities. Heart failure
hospitalizations were identiﬁed using the principal discharge
diagnosis International Classiﬁcation of Diseases, Ninth Edition
codes 428, 402.01, 402.11, 402.91, 404.91, 404.01, 404.03,
404.11, 404.13, 404.93, and 398.91. Death was ascertained
through the virtual data warehouse, which employs health
system databases, Social Security Administration vital status
ﬁles, and state death certiﬁcate registries, depending on the

Patient characteristics included demographics, reason for
admission at time of implant, cardiovascular history, family
history of sudden death, comorbidities, laboratory values and
systolic blood pressure at the time of implantation, and
cardiovascular studies (electrophysiology study performed
[yes/no], left ventricular ejection fraction, QRS duration, QRS
morphology, ﬁrst-degree atrioventricular block). Heart failure
medications prescribed at discharge following device implantation were also considered, as they are known to inﬂuence
mortality and hospitalization outcomes and may also inﬂuence
inappropriate shocks.
To avoid case-wise deletion, missing values were imputed.
Variables were generally missing infrequently (<0.5%); in
these cases, continuous variables were imputed using the
median value of known measurements in the population and
categorical variables were imputed as the most common
response in the population. Because atrioventricular conduction (6.0%) and intraventricular conduction (5.9%) were more

2787 First time primary prevention ICDs
January 2006-December 2009

1244 Excluded
431 were not enrolled in health plan at time of implant
57 had left ventricular ejection fraction >35%

1543 Patient records evaluated

501 Excluded for Pacing Indication
39 second or third degree heart block
4 bradycardic arrest
158 abnormal sinus node function
86 permanent pacemaker
214 syncope

1042 Final Study Cohort

Figure 1. Assembly of study cohort of adults receiving single- vs dual-chamber implantable cardioverterdeﬁbrillator (ICD) therapy for primary prevention of sudden cardiac death and no indication for pacing.
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heart block, previous bradycardic arrest, abnormal sinus node
function, or a documented paced rhythm. The ﬁnal analytic
cohort included 1042 patients (Figure 1).
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Statistical Analysis
Baseline characteristics of patients receiving single- and dualchamber devices were compared using t tests for continuous
variables and chi-square tests for categorical variables. Death
was considered as a competing risk for inappropriate shock
and hospitalization outcomes. Cox regression was used to
estimate the cause-speciﬁc hazard of device-type effects. The
crude hazard ratios (HRs) and corresponding 95% conﬁdence
intervals (CIs) were estimated accounting for clustering by
hospital by including hospital as a random effect.
To create more comparable treatment groups, we ﬁt a
propensity score model using logistic regression for treatment
with a dual-chamber (versus single-chamber) device, and then
applied the stabilized inverse probability of treatment weight
in the analysis of outcomes. In the propensity of treatment
model, the linearity and function forms of continuous
variables were veriﬁed by graphic evaluation. Colinearity
among variables was also examined. The probability that a
patient received a dual-chamber ICD was modeled as a
function of the patient, clinician, and hospital characteristics
in Table 1, except for medications prescribed at discharge,
which were subsequently accounted for in Cox models.
Hospitals were included as a random effect in the propensity
model to account for the clustering of patients within the
same hospitals. The propensity score model was evaluated for
its overlap of propensity score distribution. Because of a few
outliers of propensity score in our cohort, the trimmed
stabilized inverse probability of treatment weight was calculated for each patient. The trim was based on 5 and 95
percentiles of propensity scores. All patients were included in
the weighted analysis. Standardized differences were examined in the weighted sample to assess the balance of
measured baseline covariates between patients receiving
single- and dual-chamber ICDs. Small absolute differences in
standardized mean differences (<0.10) support the assumption of balance of observed variables between treatment
groups.21
DOI: 10.1161/JAHA.117.006937

The associations of ICD type with the outcomes were
evaluated in multivariable Cox proportional hazards models
using trimmed stabilized weights. Models further adjusted for
unbalanced covariates as well as medications (b-blockers,
angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers, and spironolactone) prescribed at discharge because these therapies could inﬂuence future risk of
inappropriate shock. To account for clustering of patients by
hospital, frailty models were used with hospital included as a
random effect. For inappropriate shock, patients were not
censored if they had an appropriate or uncertain shock. For
the outcomes of time to ﬁrst inappropriate shock and allcause hospitalization, patients were censored at health plan
disenrollment or death. For the outcome of death, patients
were censored at the time of last documented encounter
regardless of the continuity of health plan enrollment. The
proportional hazards assumption for ICD treatment was
evaluated by testing the interaction of treatment and time.
A secondary analysis of time to ﬁrst inappropriate shock was
performed including device settings in the model.
Because 13.5% of shocks (51/377) were classiﬁed as
uncertain by the adjudication panel, a sensitivity analysis was
performed. In the “best-case” scenario (an assumption
favoring dual-chamber devices), all uncertain shocks among
dual-chamber devices were classiﬁed as appropriate and all
uncertain shocks among single-chamber devices were classiﬁed as inappropriate. In the “worst-case” scenario (an
assumption favoring single-chamber devices), all uncertain
shocks among dual-chamber devices were classiﬁed as
inappropriate and all uncertain shocks among single-chamber
devices were classiﬁed as appropriate. All statistical analyses
were performed using SAS version 9.4 software (SAS Institute
Inc).

Results
The study population consisted of 1042 patients receiving a
ﬁrst time primary prevention ICD with no pacing indication.
There were 563 (54.0%) single-chamber devices and 479
(46.0%) dual-chamber devices, with use of dual-chamber
devices ranging from 8.4% to 85.8% by site. Patients who
received dual-chamber devices were older; more likely to be
black or Hispanic; have a history of chronic lung disease,
hypertension, ischemic heart disease, or ventricular tachycardia; and have ﬁrst-degree atrioventricular block and a
wider QRS duration (Table 1). In the weighted sample, the
absolute value of standardized difference in measured
covariates between device types was <0.10 for all except 3
of the 33 total variables (Table 2).
During a median follow-up of 2.0 years for device therapies, 17.3% received any shock, 6.6% (n=69) received at least
one inappropriate shock (6.9% for single versus 6.3% for dual,
Journal of the American Heart Association
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frequently missing, a dummy variable for missing status was
employed.
Device setting data were available in 971 (93.2%) patients.
Device settings were abstracted from surgical implant notes
and device interrogation reports and included arrhythmia
detection enhancements (on/off) and the tachycardia rate
threshold for delivery of ICD therapy. The lowest programmed
rate threshold, regardless of arrhythmia detection zone, was
categorized as <180, 180 to 199, and >200 beats per minute.
When available, settings at the time of implant were
considered. If device settings were missing at the time of
implant, but available by interrogation report at the time of
inappropriate shock, those settings were considered.
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Table 1. Baseline Patient, Physician, and Hospital Characteristics by Single- and Dual-Chamber ICD Device Type
Total
(N=1042)

Single-Chamber
(n=563)

Dual-Chamber
(n=479)

P Value

Age, meanSD, y

65.111.6

62.412.1

68.210.2

<0.001

Women, No. (%)

232 (22.3)

134 (23.8)

98 (20.5)

0.196

White

618 (59.3)

355 (63.1)

263 (54.9)

Black

171 (16.4)

80 (14.2)

91 (19.0)

Hispanic

169 (16.2)

80 (14.2)

89 (18.6)

Other/unknown

84 (8.1)

48 (8.5)

36 (7.5)

Race/ethnicity, No. (%)

0.020

<0.001

Reason for admission
Admitted for ICD, No. (%)

920 (88.3)

521 (92.5)

399 (83.3)

Other

122 (11.7)

42 (7.5)

80 (16.7)

136 (13.1)

67 (11.9)

69 (14.4)

0.232

Chronic lung disease

183 (17.6)

78 (13.9)

105 (21.9)

0.001

Diabetes mellitus

444 (42.6)

227 (40.3)

217 (45.3)

0.105

Hypertension

742 (71.2)

352 (62.5)

390 (81.4)

<0.001

Renal failure––dialysis

20 (1.9)

14 (2.5)

6 (1.3)

0.148

Family history of sudden death

38 (3.6)

27 (4.8)

11 (2.3)

History and risk factors, No. (%)
Cerebrovascular disease

NYHA, No. (%)

0.032
0.006

Class I

178 (17.1)

80 (14.2)

98 (20.5)

Class II

671 (64.4)

386 (68.6)

285 (59.5)

Class III or IV

193 (18.5)

97 (17.2)

96 (20.0)

Atrial fibrillation/atrial
flutter, No. (%)

219 (21.0)

118 (21.0)

101 (21.1)

0.960

Ventricular tachycardia, any

179 (17.2)

80 (14.2)

99 (20.7)

0.006

Nonischemic dilated
cardiomyopathy

361 (34.6)

219 (38.9)

142 (29.6)

0.002

Ischemic heart disease

673 (64.6)

343 (60.9)

330 (68.9)

0.007

Myocardial infarction

602 (57.8)

310 (55.1)

292 (61.0)

0.055

Coronary artery bypass surgery

309 (29.7)

169 (30.0)

140 (29.2)

0.781

Percutaneous coronary
intervention

357 (34.3)

189 (33.6)

168 (35.1)

0.610

Valve repair/replacement

48 (4.6)

32 (5.7)

16 (3.3)

0.072

Heart failure

909 (87.2)

481 (85.4)

428 (89.4)

0.059

Electrophysiology
study performed

24 (2.3)

15 (2.7)

9 (1.9)

0.400

Ejection fraction, meanSD

25.06.0

24.85.8

25.26.2

0.164

QRS duration, meanSD, ms

113.826.8

111.325.0

116.628.5

0.012
<0.001

Atrioventricular conduction,
No. (%)
Normal

818 (78.5)

444 (78.9)

374 (78.1)

First-degree atrioventricular block

161 (15.5)

65 (11.5)

96 (20.0)

Missing

63 (6.0)

54 (9.6)

9 (1.9)
Continued
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Table 1. Continued
Total
(N=1042)

Single-Chamber
(n=563)

Dual-Chamber
(n=479)

P Value

Normal

610 (58.5)

332 (59.0)

278 (58.0)

<0.001

Left bundle branch block

145 (13.9)

73 (13.0)

72 (15.0)

Right bundle branch block

85 (8.2)

33 (5.9)

52 (10.9)

Other

141 (13.5)

73 (13.0)

68 (14.2)

Missing

61 (5.9)

52 (9.2)

9 (1.9)

Intraventricular conduction, No. (%)

Creatinine mg/dL, meanSD

1.31.0

1.30.8

1.41.1

0.053

Blood urea nitrogen, mg/dL, meanSD

23.312.6

23.213.2

23.511.9

0.387

Sodium, mEq/L, meanSD

139.03.2

139.23.3

138.73.0

0.001

Systolic blood pressure, mm Hg, meanSD

123.319.0

120.618.1

126.319.6

<0.001

ARB

210 (20.2)

126 (22.4)

84 (17.5)

0.052

ACEI

731 (70.2)

392 (69.6)

339 (70.8)

0.687

b-Blocker

947 (90.9)

518 (92.0)

429 (89.6)

0.172

Aldosterone

355 (34.1)

196 (34.8)

159 (33.2)

0.583

<25

153 (14.7)

42 (7.5)

111 (23.2)

25 to ≤100

794 (76.2)

499 (88.6)

295 (61.6)

Discharge medications

Physician characteristics
<0.001

Physician annual ICD implants, No. (%)

>100

95 (9.1)

22 (3.9)

73 (15.2)

778 (74.7)

412 (73.2)

366 (76.4)

≤50

215 (20.6)

158 (28.1)

57 (11.9)

>50 to ≤200

199 (19.1)

118 (21.0)

81 (16.9)

>200

628 (60.3)

287 (51.0)

341 (71.2)

≤500

844 (81.0)

431 (76.6)

413 (86.2)

>500

198 (19.0)

132 (23.4)

66 (13.8)

Physician training adult electrophysiology

0.232

Hospital characteristics, No. (%)
<0.001

Hospital annual ICD implants

<0.001

Patients beds

ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ICD, implantable cardioverter-deﬁbrillator; NYHA, New York Heart Association classiﬁcation.

P=0.67), and 3.6% (n=37) received at least one shock of
uncertain appropriateness (4.3% for single versus 2.7% for
dual, P=0.18). The most common cause of inappropriate
shock was atrial ﬁbrillation/supraventricular tachycardia
(81.0%), followed by sensing abnormality (17.5%). The cause
of inappropriate shock did not differ by device type (P=0.72).
The total number of inappropriate shocks did not differ by
device type. Among those with a single-chamber device, 52%
(n=125) of shocks were appropriate, 33% (n=80) were
inappropriate, and 14% (n=35) were uncertain. Among those
with a dual-chamber device, 47% (n=64) of shocks were
appropriate, 42% (n=57) were inappropriate, and 12% (n=16)
DOI: 10.1161/JAHA.117.006937

were uncertain (P=0.26 for comparison by device type).22
There was no difference between device type in unadjusted
cumulative incidence analysis of time to ﬁrst inappropriate
shock (Gray’s test for equality, P=0.75; Figure 2) or in an
unadjusted Cox model accounting for clustering by hospital
(HR, 0.91; 95% CI, 0.60–1.38 [P=0.65] for dual- versus singlechamber ICD). In multivariable analysis, the risk of inappropriate shock was not signiﬁcantly different for dual- versus
single-chamber devices (HR, 0.91; 95% CI, 0.59–1.38
[P=0.65]).
A secondary analysis was performed among the 981 (93%)
patients with device setting data. After accounting for device
Journal of the American Heart Association
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Table 2. Continued

Single

Dual

Standardized
Difference

Normal

82.4

80.6

0.046

First-degree atrioventricular
block

11.0

13.6

Missing

6.6

5.7

Normal

59.0

59.2

Left bundle branch block

13.5

12.1

6.9

7.3

Atrioventricular conduction

Single

Dual

Standardized
Difference

Age, mean, y

64.8

64.5

0.029

Women

24.0

22.1

0.046

White

62.9

59.2

0.075

Black

12.9

16.8

Hispanic

15.4

14.3

Other/unknown

8.8

9.7

0.032

Right bundle branch block
Other

14.2

15.7

Admitted for ICD

86.7

87.5

0.022

Missing

6.4

5.7

Other

13.3

12.5

Creatinine, mg/dL, mean

1.31

1.35
24.2

11.6

12.4

0.026

Blood urea nitrogen,
mg/dL, mean

24.6

Cerebrovascular disease
Chronic lung disease

17.5

21.6

0.104

Sodium, mEq/L, mean

138.9

139.2

0.086

Diabetes mellitus

38.2

37.3

121.9

122.6

0.037

Hypertension

67.7

69.0

0.028

Systolic blood pressure,
mm Hg, mean

Dialysis

1.9

2.0

0.006

Family history of
sudden death

3.6

3.6

0.017

Race/ethnicity

0.107
0.031

Reason for admission

0.022

History and risk factors

0.019

0.005

NYHA
Class I

15.7

12.4

Class II

65.6

65.9

0.094
0.006

Class III and IV

18.7

21.6

0.074

Atrial fibrillation/atrial
flutter

27.1

28.5

0.03

Ventricular
tachycardia, any

18.3

17.3

0.026

Ventricular tachycardia,
none

81.7

82.7

0.026

Nonischemic dilated
cardiomyopathy

37.0

37.7

0.014

Ischemic heart disease

62.0

61.6

0.007

Myocardial infarction

53.1

52.2

0.019

Coronary artery
bypass surgery

26.3

30.5

Percutaneous coronary
intervention

31.8

27.5

Valve replacement/repair

6.1

6.6

0.082
0.037

Intraventricular conduction
0.005
0.043
0.015
0.041
0.028
0.057
0.03

Physician characteristics
No. of physician annual ICD implants
<25

15.2

15.8

>25 to ≤100

77.0

75.0

>100

7.8

9.1

0.048

72.9

76.4

0.083

Adult electrophysiology training

0.046

Hospital characteristics
No. of hospital annual ICD implants
≤50

23.1

15.9

0.182

>50 to ≤200

19.7

19.2

0.014

>200

57.2

64.9

0.159

≤500

79.9

81.7

0.046

>500

20.1

18.3

Patient beds

0.046

ICD indicates implantable cardioverter-deﬁbrillator; NYHA, New York Heart Association
Classiﬁcation.

0.093
0.094
0.017

Heart failure

86.5

87.8

Electrophysiology
study performed

3.4

2.3

0.068

Ejection fraction, mean, %

25.1

25.1

0.001

QRS duration, mean, ms

113.359

113.168

0.007

0.04

Continued
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Table 2. Standardized Difference in Patient, Physician, and
Hospital Characteristics Between Single- and Dual-Chamber
Device Type in a Propensity Score Weighted Sample

settings, the hazard of inappropriate shock was not signiﬁcantly different between single- and dual-chamber devices
(HR, 0.89; 95% CI, 0.58–1.38 [P=0.65]).
We also performed secondary analyses assigning all
uncertain shocks as appropriate or inappropriate as speciﬁed
above. In the best-case scenario for dual-chamber devices,
there was a lower hazard of inappropriate shock with dualchamber devices, but the difference was of marginal statistical signiﬁcance (HR, 0.67; 95% CI, 0.45–1.00 [P=0.05]). In
the worst-case scenario, dual-chamber devices were not
Journal of the American Heart Association
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Cumulative Incide
ence

0.08

0.06

0.04

Single chamber ICD

0.02

Dual chamber ICD
0.00
0.0

0.5

1.0

1.5

2.0

2.5

3.0

Years since implant

Figure 2. Cumulative incidence curves of time to each outcome
by device type. ICD indicates implantable cardioverter-deﬁbrillator.

signiﬁcantly associated with inappropriate shock (HR, 1.08;
95% CI, 0.72–1.62 [P=0.72]). The estimates in the best- and
worst-case scenarios restricted to patients with recorded
device settings were similar.
During a median follow-up of 2.4 years, all-cause hospitalization and heart failure hospitalization were not signiﬁcantly different by device type in unadjusted analysis (HR,
1.13; 95% CI, 0.92–1.39 [P=0.26] and HR, 1.00; 95% CI, 0.70–
1.43 [P=1.0], respectively) or in multivariable analysis, (HR,
1.03; 95% CI, 0.87–1.21 [P=0.76] for all-cause hospitalization
and HR, 0.93; 95% CI, 0.72–1.21 [P=0.59] for heart failure
hospitalization).
The overall mortality rate was 24.6% (n=256) over a
median of 2.9 years. Mortality was not signiﬁcantly different
by device type in unadjusted analysis (HR, 1.25; 95% CI, 0.98–
1.60 [P=0.07]) or in multivariable analysis (HR, 1.19; 95% CI,
0.93–1.53 [P=0.17]).

Discussion
In this cohort of patients without an indication for pacing
receiving an ICD for primary prevention in clinical practice, the
use of a dual-chamber device was not associated with
signiﬁcantly lower risks of inappropriate shock, death, or
hospitalization. Even after accounting for device programming, inappropriate shocks did not differ between single- and
dual-chamber devices. These results have important implications for the standard of care for patients receiving primary
prevention ICDs.
Randomized trials of single- versus dual-chamber devices to
reduce inappropriate therapies have been inconclusive.10–12
Similarly, clinical trials comparing settings that simulate a
single-chamber device with settings that utilize both leads
among patients who have all received dual-chamber devices
are also conﬂicting.14–17 A limitation and one potential
explanation for the variable results of these trials is that they
included patients who received an ICD for secondary prevention. Arrhythmia characteristics and shock rates may differ
DOI: 10.1161/JAHA.117.006937

among patients with secondary prevention, among whom
ventricular tachycardia tends to occur at a slower rate with
greater overlap with supraventricular tachycardia.9 This limits
the value of these trials in directing device selection in patients
who receive devices for primary prevention, who comprise the
majority of patients undergoing device implantation.23 A recent
trial limited to patients with primary prevention without a
pacing indication and using standardized optimal programming
strategies for single- and dual-chamber ICDs found a 2%
inappropriate shock rate over 1 year and no difference
between single- and dual-chamber devices.13
Another potential explanation for the mixed results of prior
trials is differences in the programming of devices. Recent
trials of programming strategies demonstrate that higher
detection rates and longer detection intervals reduce inappropriate therapy and mortality among primary prevention
patients.24,25 These advanced programming strategies to
reduce shock burden were not used in previous comparisons
of dual- versus single-chamber ICDs. However, these effective
programming strategies do not require a dual-chamber device.
Although the programming strategies have evolved since the
time the devices in this study were implanted, one would
expect any beneﬁt of dual-chamber devices to be more
apparent in a cohort with older programming strategies. Our
study was not designed to evaluate the mechanistic performance of single- versus dual-chamber rhythm discrimination,
but rather to evaluate the real-world effectiveness and
outcomes of a treatment strategy of dual-chamber selection.
As such, our ﬁndings add materially to the current understanding of the role of dual-chamber devices in reducing
inappropriate shocks among primary prevention recipients in
contemporary community practice.
Data comparing single- and dual-chamber devices with
regard to inappropriate shock in clinical practice are also
limited. A report from the Danish ICD Registry of 1609 patients
receiving primary prevention ICDs from 2007 to 2011 found a
higher risk of inappropriate shock with dual-chamber compared with single-chamber devices.26 However, device settings
were not collected, the population was not limited to those
without a pacing indication, and patients who received cardiac
resynchronization therapy were included. Another report from
a French registry of 2538 primary prevention devices
implanted from 2002 to 2012 found a higher rate of procedural
complications and generator replacements with dual-chamber
devices and no differences in appropriate shocks, inappropriate shocks, or mortality. However, the registry did not exclude
those with pacing indications; no adjustment was made for
patient, provider, or hospital characteristics; and device
programming was not collected in the registry. Thus, our study
expands the current understanding of the outcomes of patients
undergoing the strategy of dual-chamber devices in contemporary practice in the United States.
Journal of the American Heart Association
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Study Limitations and Strengths
The results of this study should be interpreted in the context of
the following limitations. First, 38 patients received at least
one shock for which the appropriateness of shock therapy was
uncertain based on available interrogation and clinical record
DOI: 10.1161/JAHA.117.006937

data. However, results were consistent in a sensitivity analysis
assigning uncertain shocks based on best-case and worst-case
scenarios. Further, the availability of adjudicated shock data is
a signiﬁcant strength of this study and is unique to this clinical
practice population. Second, programming of devices was not
standardized. However, we were able to account for programmed detection rate and discrimination algorithms among
a large subset of the cohort studied. Similarly, longitudinal
data on device settings were not available. However, implant
settings remain relevant for the outcome of time to ﬁrst
inappropriate shock. Reprogramming of the device may occur
at any time but is more likely following an inappropriate shock.
Third, follow-up was limited to up to 3 years, while the risk of
inappropriate shocks persists over a lifetime. However, the
median follow-up of 2 years is aligned with other studies of
outcomes in patients with left ventricular systolic dysfunction.
Third, we did not capture lead or generator revisions. Within
the follow-up time, patients may have undergone lead or
generator revisions, including upgrades from single- to dualchamber devices or to cardiac resynchronization therapy.
However, we expect the rate of revisions for the purpose of
upgrade to be low within this time frame. Finally, selection bias
may be present in those who received single- versus dualchamber devices because treating physicians may have been
more likely to implant a dual-chamber device in patients who
they felt might have a greater need for rhythm discrimination.
Thus, the similar rate of inappropriate shock observed
between single- and dual-chamber devices in this study may
not be the same if patients were randomized to single- or dualchamber devices. However, propensity score weighting should
mitigate this concern. Similarly, the data are observational and
residual confounding by unmeasured confounders cannot be
fully excluded despite our ability to account for a wide range of
measured potential confounders.

Conclusions
Among a cohort of patients without pacing indications who
received an ICD for primary prevention in contemporary
community practice, dual-chamber ICDs were not associated
with a lower risk of inappropriate shocks, hospitalization, or
death. This study adds to the literature comparing singleversus dual-chamber ICDs with regard to inappropriate
shocks, informing the selection of devices in patients
undergoing primary prevention ICD therapy and supporting
the use of simpler, less expensive single-chamber devices
unless a compelling indication for pacing is identiﬁed.
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Given the higher cost of dual-chamber devices, the absence
of beneﬁt in outcomes suggests that the use of dual-chamber
devices without a pacing indication does not represent highvalue health care. Despite the absence of compelling evidence
to support the use of dual-chamber ICDs, they are used in a
large proportion of patients in the United States who receive
primary prevention ICD therapy who do not have an indication
for pacing.1 The routine implantation of single-chamber ICDs
rather than dual-chamber devices could save an estimated
$200 million annually in the United States.13 The costs of
generator replacements, complications, and lead replacements should also be considered, as battery life is typically
shorter, complications are more common, and the potential for
lead failure is greater with dual-chamber devices.1,27 Our study
provides additional information that in real-world settings,
dual-chamber devices do not reduce inappropriate shocks.
Additional evidence is needed to identify the subset of patients
who systematically beneﬁt from dual-chamber devices, which
would greatly improve the cost-beneﬁt ratio of this therapy.
An important observation in our study was the relatively low
rate of inappropriate shocks compared with the rates reported
in the primary prevention trials that were published a decade or
more ago.28,29 The lower shock rate observed in more
contemporary cohorts may be related to optimized programming such as higher rate detection thresholds.26,30 The lower
rates of inappropriate shock in contemporary practice, while
beneﬁcial to patients, increase the challenges of demonstrating
the beneﬁts of additional interventions such as dual-chamber
devices. However, given the greater cost and risk, the beneﬁt of
dual-chamber devices should be proven to justify their use.
Based on data from randomized controlled trials, in which
the inappropriate shock rate was 20%, this sample size
provided 80% power to detect a minimum absolute difference in
rates of 7.3%. However, the rate of inappropriate shock in this
cohort was much lower. With our sample size and observed
inappropriate shock rate of 6.6%, we had 80% power to detect a
minimum absolute difference of 4.5%. The low rate of
inappropriate shock in our study highlights the challenges in
identifying the beneﬁts of strategies designed to further reduce
the risks of inappropriate shocks. Ultimately, treatment
strategies associated with higher costs and complications
should be proven effective before they are widely implemented.
In the case of dual-chamber ICDs among patients without
pacing indications, the proof of effectiveness in improving
outcomes, including inappropriate shocks, is not available.
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